MCF7A BCAR3 [MCF7-BCAR3] cell line

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

• Name: MCF7A BCAR3 [MCF7-BCAR3] cell line
• Alternate name: Breast Cancer Anti-Estrogen Resistance 3; SH2 Domain-Containing Protein 3B; NSP2
• Cancer: Gynaecologic cancer
• Cancers detailed: Estrogen dependent;Mammary adenocarcinoma
• Research fields: Cancer;Drug development
• Tool sub type: Continuous
• Parental cell: MCF7A
• Organism: Human
• Tissue: Breast
• Disease: Cancer
• Model: Cancer Model
• Description: Breast cancer is widely and effectively treated with endocrine treatment. However, in many disease cases the tumours will eventually progress into an estrogen-independent and therapy-resistant phenotypeSeven genes including AKT1, AKT2, BCAR1, BCAR2, BCAR3, EGFR2 and GRB7 have been shown to directly underlie estrogen independence in MCF7A human breast cancer cells. This cell line is part of a panel of 4 cell lines (Cat No 154636-154638, 154643) which have been transfected with these genes, plus the parental (Cat No 154546)These cell lines are a powerful tool for studying the molecular and cellular mechanisms of breast tumour progression, therapy resistance and to test the effectiveness of novel drugs to combat different modes of anti-estrogen insensitivity
• Production details: Full length BCAR3 cDNA was introduced in the estrogen-dependent MCF7A cell line by transfection with lipofectamine
• Biosafety level: 1

Target Details

• Target: BCAR3

Applications

• Application notes: This cell line is also resistant to Geneticin which may be included in the culture to maintain the expression plasmid

Handling

• Format: Frozen
• Growth medium: RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum (FCS)
• Unit size: 1x10^6 cells / vial
• Shipping conditions: Dry ice
• Storage conditions: Liquid Nitrogen
• Mycoplasma free: Yes

References

• van Agthoven et al. 1998. EMBO J. 17(10):2799-808. PMID: 9582273.